China SXT Finalizes $12M Offering With Zero-Price Warrants That Could Add 72M Shares
SXTC sits 49% above its 52-week low of $0.23 on elevated volume (13× avg).
Summary
China SXT finalized a $12M offering with zero-price exercise warrants that could issue up to 72M additional shares at no cash cost to warrant holders, causing immediate $17.27/share dilution to existing shareholders. The offering closed on October 9, 2026.
Updated with an SEC 6-K filing · What changed
Updates
· SEC 6-K — The offering closed on October 9, 2026, with Univest Securities as placement agent receiving a 7% cash fee and up to $50,000 expense reimbursement.
Key Events · Financing and Capital Events · SXTC
-
Updated · · SEC 6-K
$12M Offering Finalized and Closed
8,000,000 units priced at $1.50 each, with an over-allotment option for 8,000,000 more units. Gross proceeds up to $12M, with $11.16M net after 7.0% placement agent fees. The offering closed on October 9, 2026, with Univest Securities as placement agent receiving a 7% cash fee and up to $50,000 expense reimbursement.
-
Zero-Price Exercise Warrants
Ordinary warrants have a $2.75 exercise price but include a zero price exercise feature. At the $0.50 floor price, holders could receive up to 72M shares (144M with over-allotment) with no cash proceeds to the company.
-
Massive Dilution to Existing Shareholders
Existing shareholders face an immediate $17.27 per share decrease in net tangible book value. Share count could grow from 2.36M to 82.36M shares (or 162.36M with over-allotment) if all warrants are exercised via zero price.
-
Rapid-Fire Capital Raising Pattern
This follows a $9M offering in July 2026, a terminated $3M private placement on October 7, and a $12M offering announced October 8. The company is aggressively raising capital amid a declining share price.
Analysis · SXTC · Life Sciences
The finalized terms of China SXT Pharmaceuticals' $12 million registered direct offering carry a highly dilutive twist: units priced at $1.50 each include warrants exercisable at $2.75, but a zero price exercise feature lets holders receive shares without paying cash, with the share count rising as the stock falls. At the $0.50 floor price, this could add up to 72 million shares—or 144 million with the over-allotment—with zero cash proceeds to the company. Existing shareholders face an immediate $17.27 per share reduction in net tangible book value. This structure punishes existing holders as the stock declines, and it comes just one day after the company terminated a $3M private placement amid a series of rapid-fire capital raises. The offering closed on October 9, 2026, with Univest Securities as placement agent receiving a 7% cash fee and up to $50,000 expense reimbursement.
How filings like this one have moved
In the 30 days to Oct 9, 2026, 44% of the 307 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.58%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SXTC was trading at $0.34 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $312.5K. The 52-week trading range was $0.23 to $83,758.24. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.